Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 6Lymphoid 6Plasma cell 5Tumor-Agnostic 2Thoracic 2Myeloid 2Gynecologic 2Genitourinary 2Breast 2Sarcoma 1Head & Neck 1Gastrointestinal 1

Conditions

Urinary Bladder Neoplasms 1Prostatic Neoplasms 1Carcinoma in Situ 1

Interventions

pembrolizumab 182Magnetic Resonance Spectroscopy 163Specimen Handling 135enzalutamide 126Nivolumab 124Gemcitabine 99Docetaxel 96Radiosurgery 92Prednisone 85Androgen Antagonists 82Abiraterone Acetate 81Radiotherapy 75apalutamide 68Cisplatin 65darolutamide 63Ipilimumab 63Biopsy 60abiraterone 58Carboplatin 56cabozantinib 55Leuprolide 53enfortumab vedotin 49Radiation 48Pluvicto 45Standard of Care 44atezolizumab 40Surveys and Questionnaires 39acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 37X-Rays 37avelumab 35

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Diphenhydramine × Genitourinary × 1 year × Clear all
NCT03258593 2026-03-17

Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
15 enrolled 21 charts
Genitourinary

Urinary Bladder Neoplasms, Carcinoma in Situ

NCT03493945 2025-09-30

Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
59 enrolled 20 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡